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Antibiotic-loaded poly(methyl methacrylate) bone cements (ALBCs) are widely used in total
joint replacement (TJR), for local delivery of antibiotics to provide prophylaxis against pros-
thetic joint infections (PJI). One of the shortcomings of the current generation of ALBCs is
that the antibiotic release profile is characterized by a burst over the first few hours followed
by a sharp decrease in rate for the following several days (often below minimum inhibitory
concentration (MIC)), and, finally, exhaustion (after, typically, ~ 20 d). This profile means
that the ALBCs provide only short-term antimicrobial action against bacterial strains
involved PJI.
Rationale
The purpose of the present study was to develop an improved antibiotic delivery system for
an ALBC. This system involved using a layer-by-layer technique to load the antibiotic (gen-
tamicin sulphate) (GEN) on silica nanoparticles, which are then blended with the powder of
the cement. Then, the powder was mixed with the liquid of the cement (NP-GEN cement).
For controls, two GEN-loaded brands were used (Cemex Genta and Palacos R+G). Genta-
micin release and a host of other relevant properties were determined for all the cements
studied.
Results
Compared to control cement specimens, improved GEN release, longer antimicrobial activ-
ity (against clinically-relevant bacterial strains), and comparable setting time, cytocompat-
ibility, compressive strength (both prior to and after aging in PBS at 37 oC for 30 d), 4-point
bend strength and modulus, fracture toughness, and PBS uptake.
Conclusions
NP-GEN cement may have a role in preventing or treating PJI.
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Introduction
Total joint replacements (TJRs), such as hip and knee replacements, are increasingly used
worldwide because of the “graying” of population and risk factors such as obesity [1, 2]. More
than 1 million total hip and knee replacement (THJRs and TKJRs) are performed annually in
the United States [3] and>180000 such replacements were performed in the UK during 2016
[4]. Periprosthetic joint infections (sometimes also called prosthetic joint infections (PJI)) are
a serious adverse event that not only reduces success rate of TJRs, resulting in the need for revi-
sion surgery, but, sometimes, leads to patient death [5, 6]. The treatment of such infections is
complex, usually involving aggressive surgical intervention (debridement) and long antimicro-
bial therapy, which negatively impacts a patient’s quality of life and places a huge burden on a
health care system [7, 8].
In many THJRs and TKJRs, the anchoring agent is a PMMA bone cements bed and antibi-
otic-loaded PMMA bone cements (ALBCs) are used both as a prophylaxis against as well as
treatment for PJI [9, 10]. The most common antibiotics employed in commercially available
ALBC are aminoglycosides, in particular gentamicin sulphate [11]. Gentamicin sulphate is
thermostable and can withstand the exothermic polymerization reaction of PMMA bone
cement. It is also available in powder form which makes it ideal for mixing with the cement
powder as a premixed or off-label formulation [12].
There are many concerns about ALBCs, in particular, the release profile of the antibiotic
[13, 14]. Specifically, the profile comprises a burst for the first few hours after surgery, followed
by slow release below inhibitory levels within a few days [15]. This release profile does not pro-
vide long-term prophylaxis against early- and delayed- stage infections (defined as infections
that are contracted during the first 24 h-1 wk and after 1 mo, respectively) [16–20]. In addi-
tion,<10% of the antibiotics is released, with the rest trapped within the hydrophobic PMMA
matrix [18, 19]. Thus, there is scope for development of ALBCs that display improvements in
the aforementioned features of antibiotic release without compromise of other properties of
the curing and cured cement.
Layer-by-layer assembly (LbL) comprises deposition of alternatively oppositely-charged
polyelectrolytes on different substrates, allowing control of the composition and thickness of
the assembly at nanoscale level in a reproducible manner [21, 22]. This coating process is sim-
ple, low-cost, scalable and does not utilize harsh organic conditions, as it involves mild aque-
ous solutions. Because of these advantages, LbL has numerous applications in drug delivery
[23–25]. Nanoparticles have been extensively explored, and successfully applied, as drug carri-
ers for antibiotics and other drugs [26, 27]. Among nano-carriers, silica nanoparticles are pre-
ferred because of their unique physicochemical properties, biocompatibility and low cost [28].
Silica nanoparticles have a large surface area-to-mass ratio and are amenable to structural or
functional modification because of a silanol-containing surface [23, 29, 30].
We propose using gentamicin LbL-loaded silica nanoparticles to prolong GEN release for
several weeks (4-6 weeks) to provide prophylaxis from postsurgical PJIs. We intend using
GEN LbL loaded silica nanoparticles (NPs) previously characterised [31], developed using
poly-beta-amino-ester (PBAE) as the polycation and alginate as the polyanion, to prolong and
increase the release of GEN from a bone cement. NPs were made of 10 quadruple layers of the
sequence (alginate, gentamicin, alginate, PBAE) and have a diameter of about 50 nm. Many
approaches to extend antibiotic release from nanoparticles have been tested and it has been
shown that LbL is very effective [30].
We used two popular cement brands (Cemex and Palacos R) and determined a large collec-
tion of properties of each of these brands both as-received and after incorporation of the nano-
particles. These properties were setting time, gentamicin release, efficacy of released
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gentamicin against various bacteria (in their planktonic form) commonly causing PJI,
mechanical properties (compression, bending and fracture toughness), cytocompatibility
toward human osteoblast cells (MTT, LDH, cell calcium production, and cytoskeletal mor-
phology), and PBS uptake.
Materials and methods
Chemicals
Triton X-100, tetraethyl orthosilicate (TEOS), 3-aminopropyltriethoxysilane (APTS), sodium
alginate, gentamicin sulphate, sodium acetate trihydrate, phosphate buffer solution (PBS) tab-
lets, o-phthaldialdehyde reagent solution (OPA), piperazine, and 1,6 hexanediol diacrylate
were purchased from Sigma-Aldrich, UK. Cyclohexane, n-hexanol, ammonium hydroxide
(35%), diethyl-ether, di-chloro methane (DCM), ethanol, methanol, glacial acetic acid, and
iso-propanol were purchased from Fisher Scientific, UK. All reagents were stored according to
manufacturer’s guidelines and used as received. The bone cements brands used were Cemex
(Tecres S.p.A., Italy) and Palacos R (Heraeus Medical GmbH, Germany).
Acetic acid-sodium acetate buffer (0.1 M, pH 5) was prepared mixing sodium acetate trihy-
drate (CH3COONa�3H2O) (0.1 M) and acetic acid (CH3COOH) (0.1 M) solutions 3:7 and stir-
red, with pH checked and adjusted in the range 5.0 ± 0.1. PBS solution (pH 7.4) was prepared
according to manufacturer’s guidelines.
Poly-beta-amino-ester synthesis
Amino-terminated poly(β-amino ester)s (PBAEs) were synthesized as described in Al Thaher
et al. [31] by mixing 1,6 hexanediol diacrylate and piperazine in a 1:1.1 ratio in DCM at a con-
centration of 5 ml of DCM and 3.7 mmol of acrylate. The polymerization was performed
under stirring at 50˚C for 48 hours. PBAEs were precipitated through pouring the reaction
mixture in about 10 times the volume of diethyl-ether under vigorous mixing, after which the
solvents were removed under vacuum.
Nanoparticle preparation
Amino functionalised silica nanoparticles synthesis. Silica nanoparticles functionalised
with amine groups (SiO2-NH2) (NPs) were prepared through the Sto¨ber method in a one-pot
synthesis by hydrolysis of TEOS in reverse micro-emulsion [32] and subsequent functionaliza-
tion. In a typical synthesis, Triton X-100 (17.7 g) was mixed with 16 mL of n-hexanol, 75 mL
of cyclohexane, and 4.8 mL of deionised water under vigorous stirring. Once the solution was
transparent, 600 μL of NH4OH (29.6%) were added. The solution was subsequently sealed,
after stirring for 20 minutes 1 ml of TEOS was added and stirring continued for further 24 h.
The surface of the silica nanoparticles was functionalized with amino groups by adding 50 μl
of APTS to the micro-emulsion under stirring and incubating for further 24 hours. The NPs
were recovered by adding ethanol (200 ml) to break the microemulsion and centrifuging at
14000 rpm for 10 min (LE-80K, Ultracentrifuge, Beckman Coulter, UK) at 20˚C (35280 g).
The NPs were vigorously washed three times with deionized water. Finally, the washed nano-
particles were left to dry at room temperature in a fume hood for 24 h.
Layer by Layer (LbL) coating technique. The NPs were layered with a repeating sequence
of the polyelectrolytes (sodium alginate, PBAE) and the antibiotic (GEN), with the final assem-
bly hereafter referred to as NP-GEN, as described in Al Thaher et al. [31].
The sequence was composed of multiples units of four layers (quadruple layer). Each qua-
druple layer was made of sodium alginate, GEN, sodium alginate and PBAE. The following
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concentrations of polyelectrolytes and drug in acetic acid-sodium acetate buffer pH 5 were
used in LbL: sodium alginate (2 mg/mL), GEN (10 mg/mL), and PBAE (2 mg/mL).
The dried amino functionalized silica nanoparticles (~1 g) were placed in a test tube and
dispersed in 20 mL of sodium alginate solution and stirred for 10 minutes. Then, the dispersed
nanoparticles were centrifuged to pellet nanoparticles. After that, the supernatant was removed
and replaced with 20 mL of fresh acetic acid-sodium acetate buffer as a washing step to remove
traces of the un-layered polyelectrolyte. Then, the buffer was centrifuged and removed, leaving
the washed nanoparticles ready for next layer. 10 mL of GEN were stirred with the nanoparti-
cles for 10 min, centrifuged, and washed again with buffer. Next, sodium alginate solution was
layered again and washed. Finally, 20 mL of the PBAE solution were used to layer the fourth
layer and washed, completing the first quadruple layer. This sequence was repeated to build up
10 quadruple layers of NP-GEN.
Bone cement preparation
Four bone cement formulations were used: as-received Cemex Genta (Cemex Genta), Cemex
with incorporated NP-GEN (Cemex-NP-GEN), as-received Palacos R+G (Palacos R+G) and
Palacos R with incorporated NP-GEN (Palacos- NP-GEN). For the compositions of these
cements, see Table 1. Calculations for the nanoparticle containing bone cements were based
on the loading efficiency (30% w/w) previously determined [31], to have equal amounts of
gentamicin between commercial and nanoparticles loaded bone cements.
Cement constituents were stored at recommended conditions (20-25ºC for the powder and
8-15 ºC for the liquid in the dark) and conditioned to room temperature (23ºC) for 2 hours
before mixing [33]. Powder components were sifted before weighing and mixed thoroughly.
The resulting powder mixture and the cement liquid were hand mixed in a polypropylene
bowl with a polypropylene spatula for 1 min and then the dough was poured into polytetra-
fluoroethylene (PTFE) moulds with sizes and configurations appropriate for specimen prepa-
ration for the various cement properties to be determined. After pouring the cement dough
into a mould, two steel endplates covered in PTFE film were clamped at both ends of the
moulds. After 2 hours, the specimens were pushed out of the mould using a steel rod and
allowed to cure for 24±2 h at 23±1 ºC. Then, the specimens were sanded down to the correct
dimensions using 320 grit SiC papers.
Table 1. Composition of the test bone cements (in g�).
Palacos R+G Palacos-NP-GEN Cemex Genta Cemex-NP-GEN
Liquid component 18.80 18.80 13.30 13.30
Methyl Methacrylate 18.4 18.4 13.17 13.17
N-N Dimethyl-p-Toluidine 0.4 0.4 0.12 0.12
Hydroquinone / ppm 60.00 60.00 75.00 75.00
Powder Component 40.84 42.80 40.00 43.95
Polymethyl Methacrylate 33.12 33.12
Poly(Methyl Methacrylate, Methyl acrylate) 33.6 33.6 0.0 0.0
Chlorophyll 0.008 0.008 0.0 0.0
Benzoyl peroxide 0.3 0.3 1.20 1.20
BaSO4 0.0 0.0 4.00 4.00
Zirconium dioxide 6.1 6.1 0.0 0.0
Gentamicin sulphate 0.84 0.0 1.69 0.0
NP-GEN 0.0 2.80 0.0 5.63
� Except for hydroquinone
https://doi.org/10.1371/journal.pone.0207753.t001
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Rheology testing
These tests were performed using a rheometer (Anton Paar MRC702, Anton Paar Ltd., UK),
equipped with 6 mm diameter circular flat plates (separation distance = 1 mm). During a test,
a sinusoidal stress (σ), of small amplitude (σ0) and frequency (ω), was applied to a cement
dough, which had been placed on the lower plate. The tests were started very shortly thereafter,
with the applied strain (ε(t)) and frequency being 0.1% and 1 Hz, respectively.
Note that (i) in this test, the complex modulus of the cement (G�) is the ratio of the
response stress (σ(t)) to ε(t); (ii) G� = G´ + iG”, where G´ and G” are the storage modulus
and loss modulus of the cement, respectively; (iii) the ratio (G”/G´) = tan δ, where δ is the
phase angle between the stress and the strain signals; (iv) the test ran continuously from
when the dough was placed on the plate until it polymerized; thus, tan δ was obtained contin-
uously; and (v) the setting time of the cement is the is time the maximum of the tan δ-versus-
time curve occurs.
Each sweep experiment was carried out on three independently prepared cement samples
[34], and results are presented as mean and standard deviation.
Gentamicin release quantification
Cylindrical specimens (diameter and height = 6 mm and 10 mm respectively) were prepared
using an appropriate PTFE mould. The specimens were incubated in 3 mL PBS buffer (pH
7.4) at 37ºC. The buffer was replaced each day in order to attain sink condition, where the con-
centration of released gentamicin is negligible in comparison to its saturation solubility. The
specimens were stored in a refrigerator (2-8 ºC) for no more than 3 d prior to analysis. For
each of the cements, 6 specimens were tested; when the bone cements were mixed with nano-
particles these were independent batches.
The amount of GEN released from the nanoparticles in the buffer was quantified through
fluorescence spectroscopy using o-phthaldialdehyde reagent [35] that reacts with the amino
groups of GEN producing a fluorogenic product. 70 μL of buffer containing antibiotic were
mixed with 70 μL of iso-propanol and 70 μL of OPA reagent solution in a black 96-wells plate.
After 30 min at room temperature in the dark, the fluorescence was determined (Ex = 340 nm
and Em = 450 nm) with a fluoroscan (FLUOROstar Optina, BMG Labtech). At each time-
point, gentamicin concentration was calculated. Six independent solutions with gentamicin
concentrations ranging from 0 μg/mL to100 μg/mL were prepared for the calibration curve
and analysed concurrently for each 96-well plate run.
Antimicrobial testing
The following bacterial strains were tested: methicillin-resistant Staphylococcus aureus
(MRSA) (NCTC12493), S. aureus (NCIMB 9518and ATCC9144), Streptococcus pyogenes
(ATCC19615), Staphylococcus epidermidis (ATCC12228), Acinetobacter baumannii
(NCIMB9214), Pseudomonas aeruginosa (NCIMB10548) and Escherichia coli (NCTC10418).
In addition, 5 clinical isolates of PJI were also tested.
Each bacteria spp. was stored at -80˚C in cryo-protective solution. Viable stocks were gen-
erated by spreading the frozen stock on brain heart infusion (BHI) agar and incubating for 24
h at 37ºC. Plates were then stored at 4ºC for no more than 2 wk. Cell cultures were prepared by
inoculating a loopful of cells from an individual colony on the plates into sterile BHI broth fol-
lowed by static incubation for 24 h at 37ºC; the cell concentrations of these suspension, as
determined by standard dilution/plating technique, was ~109 colony-forming unit (CFU)/ml
for all spp. except S. pyogenes, which was~108 CFU/ml. The cell suspension was diluted 1:1000
in fresh sterile BHI broth, and 20 μL of the diluted broth were added into a sterile 96-well
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plate. After that, each well was filled with 100 μL media of a bone cement for each day of
release testing and the plate was incubated for 18-24 h at 37 ºC. On the next day, the growth in
each well was evaluated visually [36]. A sufficient growth of the tested bacteria was considered
as a positive result; that is, an obvious button or definite turbidity as compared with the posi-
tive and negative growth. Each data point was performed in triplicate for each individual strain
on 6 individual batches of cements specimens, to determine the duration of the release media
from the bone cement inhibitory activity towards bacteria growth as the day corresponding to
the last daily release inhibiting bacterial growth.
The minimum inhibitory concentration (MIC) for gentamicin was determined against the
different bacteria tested through use of a standard MIC broth dilution protocol [36].
The expected antimicrobial activity against each strain was determined as the first day cor-
responding to a GEN concentration below MIC.
Cytotoxicity testing
Saos-2 human osteosarcoma osteoblast-like cells (ATCC HTB-85) were used for cytocompat-
ibility testing. Saos-2 were cultured in RPMI-1640 medium supplemented with fetal bovine
serum (10% v/v) and 1% v/v of a solution of penicillin (5000 U/mL)/streptomycin (5000 mg/
mL). Cells were incubated at 37˚C in humidified atmosphere with 5% CO2. Cells were grown
until ~70% confluence, washed twice with sterile PBS, and detached with trypsin, and then,
osteoblast cells were counted (using Trypan Blue to differentiate between viable and nonviable
cells). The cement specimens were discs (diameter and height = 10 mm and 5mm, respec-
tively). For each of the cements, 6 specimens were tested; when the bone cements were mixed
with nanoparticles these were independent batches.
MTT. Vybrant MTT Cell Proliferation Assay Kit (V-13154) (Thermofisher scientific, UK)
was used for the determination of the number of viable cells. In a 24-well plate, each bone
cement sample was incubated in 1 mL growth media inoculated with approximately 60000
cells/well for up to 7 d at 37˚C in humidified atmosphere with 5% CO2. MTT test was done
after 1, 2, 4 and 7 d of incubation. At each time point, the medium present in the well was
taken off and replaced with 1 mL of fresh medium (phenol red-free). 20 μL of MTT reagent (5
mg/mL in PBS) were added to each well and the plate was incubated for 24 h at 37˚C in
humidified atmosphere with 5% CO2. After this, 900 mL of the media were removed from
each of the wells, and 150 μL of dimethyl sulfoxide (DMSO) were added to each well and the
plates were incubated for further 10 min. 200 μL of solution containing the dissolved formazan
was put into another 96-well plate and absorbance determined using a spectrophotometer
(Tecan Infinite F50, Austria) at 560 nm.
The media in each well was replaced with fresh media (1 mL of RPMI-1640 medium)
warmed up to 37ºC on day 4, in order to supply the cells with nutrients before testing. Replac-
ing media is only needed for the time point day 7, because the previous points (day 1, 2, 4)
were assessed before media change.
LDH. In Vitro Toxicology Assay Kit, LDH based (Sigma-Aldrich, UK) was employed to
determine viability of cells according to manufacturer’s protocols. Samples were prepared as
described above. LDH was quantified in the media (LDH released) and after adding the cell
lysis solution (LDH total). Cell viability was calculated according to the following equation:
Viability %ð Þ ¼
ðtotal LDH   LDH releasedÞ
total LDH
� 100% ð1Þ
Total and released LDH were determined as OD, at 490 nm, after correcting for the reading
from the negative control.
Si-GS nanocarriers for antimicrobial bone cement
PLOS ONE | https://doi.org/10.1371/journal.pone.0207753 December 13, 2018 6 / 22
Calcium production assay-Alizarin red. For mineralisation, the growth medium was
supplemented with 50 μM ascorbic acid-2-phosphate and 7.5 mM β-glycerophosphate. In a
24-well plate, each cement specimen was incubated in 1 mL growth media and inoculated with
approximately 60000 cells/well for 21 d at 37˚C in humidified atmosphere with 5% CO2 replac-
ing media every 3-4 days On day 21, the medium present in each well was removed and
replaced with 1 mL of glutaraldehyde 10% (v/v) (Sigma-Aldrich, UK) and the plates were incu-
bated for 15 min and washed with deionized water three times. 1 mL of Alizarin Red S 1% (w/
v) (Sigma-Aldrich, UK) was added to each well and the plates were incubated for 20 min. After
washing four times with deionized water, 1 mL of acetic acid 10% (v/v) was added to each well
and the plates were incubated for 30 min. After this, 200 μL of the solution were put in another
96-well plate and, then, analysed using a spectrophotometer (Tecan Infinite F50, Austria), at
450 nm [37].
Fluorescence imaging. Fluorescence imaging was done using specimens of Cemex Genta
and Cemex-NP-GEN. Human Saos-2 cells (4x104 cells/well) were seeded directly on glass cov-
erslips in 6-well plates and cultured in RPMI 1640 medium containing 10% FBS and 1% peni-
cillin streptomycin at 37˚C in a humidified 5% CO2 atmosphere for 24 h. After cell
attachment, the medium was replaced with 3 mL of the cement solutes obtained after incuba-
tion of the cement specimen for 24 h in RPMI 1640 medium containing 10% FBS and 1% peni-
cillin streptomycin. Cells were washed thoroughly three times in PBS 24 h later.
The viability of cells was assessed using simultaneous fluorescence staining of viable and
dead cells. Briefly, for the staining of the viable and dead cell and nuclei, cells were incubated
with calcein-AM, propidium iodide (Sigma-Aldrich, St. Louis, MO, USA), and trihydrochlor-
ide Hoechst 33342 (Thermo Fisher Scientific, Eugene, OR, USA), respectively. After washing
the cells with PBS, 3 mL of staining solution was added to each well (0.1% w/v propidium,
0.2% w/v calcein, 5 μg/mL Hoechst in PBS). Then, the cells were incubated at 37˚C for 30 min,
and the stain was removed from each, and cells were washed with PBS immediately before
imaging.
A confocal microscopy (Zeiss, Oberkochen, Germany) was used for visualization of the
staining, with the magnifying glasses used being 10X and 64X.
For the staining of the F-actin cytoskeleton and nuclei, the cells were fixed with 4% parafor-
maldehyde in PBS and permeabilized with 0.1% Triton-X-100.
Observation of cell morphology necessitated fluorescent dyes for cell staining. Thus, cells
were incubated with tetramethyl rhodamine B isothiocyanate-conjugated phalloidin (Sigma-
Aldrich, St. Louis, MO, USA) and trihydrochloride Hoechst 33342 (Thermo Fisher Scientific,
Eugene, OR, USA), respectively. 3 mL of staining solution was added to each well (50 μg/mL
fluorescent phalloidin conjugate, 5 μg/mL Hoechst in PBS). Then, the cells were incubated at
37˚C for 30 min, and the stain was removed from each and cells were washed with PBS imme-
diately before imaging.
A confocal microscopy (Zeiss, Oberkochen, Germany) was used for visualization of the
staining, with the magnifying glasses used being 10X and 64X.
Mechanical testing
Compression tests were conducted in accordance with ISO 5833 [33] using cylindrical speci-
mens (diameter and height = 6 mm and 12 mm, respectively) and a materials testing machine
(Zwick Roell ProLine table-top Z050/Z100) equipped with a dedicated software package
(TestXpert II software, Zwick Testing Machines, Herefordshire, UK) at a crosshead speed of
20 mm/min. Compressive strength was determined both before and after the test specimens
were aged in PBS, at 37˚C, for 3 mo.
Si-GS nanocarriers for antimicrobial bone cement
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Four-point bending tests were conducted in accordance with ISO 5833 [33] using rectangu-
lar specimens (length, width, and thickness = 75 mm, 10 mm, and 3.3 mm, respectively) and
the aforementioned materials testing machine and software package, at a cross-head displace-
ment rate of 5 mm/min. Bending strength and bending modulus were determined.
Fracture toughness tests were conducted in accordance with ISO 13586 ISO13586:2000
[38] using rectangular specimens (length, width, and thickness = 45.0 ± 0.1 mm, 10.0 ± 0.1
mm, and 3.3 ± 0.1 mm, respectively) with a sharp chevron notch (5.5 ± 0.5 deep) cut into the
center of one of the long sides of the specimen using a sharp razor blade. The specimen was
loaded at the center of the unnotched long face, in three-point bend mode (distance between
the support rollers = 40 mm) using the aforementioned materials testing machine and software
package, at a cross-head displacement rate of 5 mm/min.
For each combination of cement and mechanical test, 5 specimens were tested; when the
bone cements were mixed with nanoparticles these were independent batches.
PBS uptake testing
The bone cement cylindrical specimens were incubated in 3 mL PBS at 37˚C for 35 d; for the
first 2 wk, the samples were weighed daily; and, after that, they were weighed every 3 d [34]. At
each time-point, the PBS uptake of a specimen was calculated by dividing its mass gain by its
initial mass. For each cement, 3 specimens were tested; when the bone cements were mixed
with nanoparticles these were independent batches.
Statistical analysis
Each of the quantitative results is given as mean ± standard deviation. The hypothesis of nor-
mal distribution of the results was tested using the Shapiro-Wilk test, with significance
denoted when p< 0.05. Test of significance was conducted using one-way analysis of variance
(ANOVA) and significance was denoted if p< 0.05. All analyses were run using a commer-
cially available software package (IBM SPSS Statistics for Windows, version 21 (IBM Corp.,
Armonk, NY, USA).
Results
Bone cement settling time
For both Cemex and Palacos R, incorporation of NP-GEN led to an insignificant decrease in
setting time (p>0.05) (from ~4.5±0.1 min to ~ 4.3±0.1 min) (Fig 1).
Gentamicin release profile
For Cemex and Palacos R, 1) the concentration of GEN released in the media had a burst pro-
file (Fig 2) with concentration of ~315 and 150 μg/mL, respectively, after 1 d that dropped at
least an order of magnitude after 2 d; and 2) GEN release continued for about 1 wk and 2 wk
in the case of Palacos R+G and Cemex Genta, respectively (Fig 2).
When NP-GEN was added to the bone cement, the release of GEN from Cemex-NP-GEN
exhibited the same concentration after 1 d but the subsequent decrease in antibiotic released
was less pronounced and gentamicin was released for ~27 d.
A lower concentration of GEN was released from Palacos-NP-GEN than Palacos R+G after
1 d, but the release was not prolonged as GEN concentration fell below 1 μg/mL after 10 d.
Cumulative GEN release from Cemex-NP-GEN (~26%) was significantly higher than from
Cemex Genta (~10%); while, for both Palacos-NP-GEN and Palacos R+G, cumulatively, only
~9% of the initially added GEN was released.
Si-GS nanocarriers for antimicrobial bone cement
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Antimicrobial analysis
MICs for the strains ranged between 16 μg/mL for MRSA and 1 μg/mL for S. epidermidis
(Table 2 and Table 3).
Cemex-NP-GEN showed longer duration of bacterial growth inhibition compared to
Cemex Genta (Fig 3A).
For most of the bacterial species tested, Palacos-NP-GEN did not show longer antimicrobial
activity than Palacos R+G.
The expected duration of antimicrobial activity for each strain was determined as the first
day when the concentration of GEN in the release media was below the MIC. Generally, the
observed antimicrobial activity was longer than expected (if only GEN concentration was
taken into account), particularly for strains with greater MIC (Fig 3B).
Cytotoxicity analysis
MTT assay. After each of the time points (1, 2, 4 and 7 d), mitochondrial activity of osteo-
blast cells grown on bone cements samples did not differ between Palacos R+G and Palacos-
NP-GEN (p>0.05) nor between Cemex Genta and Cemex-NP-GEN (p>0.05) (Fig 4). How-
ever, after 1 d, the activity of Cemex was lower than that of Palacos R (p<0.05).
Fig 1. Sample rheological test results for Palacos R+G (a), Palacos-NP-GEN (b), Cemex Genta (c) and Cemex-NP-GEN (d).
https://doi.org/10.1371/journal.pone.0207753.g001
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LDH assay. After each of the time points (1, 2, 4 and 7 d), the viability of human osteo-
blast cells exposed to Palacos or Cemex bone cement was not affected by the addition of either
GEN or NP-GEN (p> 0.05) (Fig 5).
Alizarin red. Reduction in calcium production for osteoblasts exposed to the NP-GEN
loaded cements (Palacos-NP-GEN and Cemex-NP-GEN) was not significant compared to
their commercial counterparts (p>0.05) (Palacos R+G and Cemex Genta, respectively)
(Fig 6).
Fluorescence images. Live and dead fluorescent images of osteoblast cells for Cemex
Genta and Cemex-NP-GEN appeared to be similar (Fig 7).
Fig 2. Summary of the gentamicin release results (n=6±SD).
https://doi.org/10.1371/journal.pone.0207753.g002
Table 2. Gentamicin MIC of catalogues strains tested.
Strain MIC (μg/mL)
S. aureus NCIMB 9518 8
S. aureus ATCC 9144 1
S. epidermidis ATCC12228 1
MRSA NCTC12493 15.5
S. pyogenes ATCC12344 8
E. coli NCTC14418 8
P. aeruginosa PA01 8
A. baumannii NCIMB 9214 2
https://doi.org/10.1371/journal.pone.0207753.t002
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Actin staining suggests bone cement specimens were a substrate for which the cells have
some, albeit poor, compatibility (Fig 8). Osteoblast cells are totally spreading, especially con-
sidering the number of filopodia apparent at the higher magnification (Fig 8B and 8D). The
normal trapezoidal morphology of osteoblast-like cells is missing, as are the stress filaments
characteristic of well-spread osteoblasts.
Mechanical properties
NP-GEN-containing bone cements had similar compressive strength to the commercial ones
both before and after ageing of the specimens (p>0.05) (Fig 9). Palacos cements had higher
compressive strength than Cemex strength (p>0.05). Aging of test specimens resulted in
decrease of compressive strength of Cemex specimens (p<0.05) but not for Palacos specimens
(p>0.05).
Cemex-NP-GEN showed similar bending strength, bending modules, and fracture tough-
ness to the corresponding values for Cemex Genta (p>0.6) (Table 4).
PBS uptake testing
Overall, PBS uptake by Cemex-NP-GEN specimens was comparable to that by Cemex Genta
specimens up to 35 d (p>0.05) (Fig 10).
Discussion
TJRs are performed on patients affected by end stage osteoarthritis (OA). These procedures
are conducted with increasing frequency because of the increasing incidence of OA that is
driven by the ageing population and obesity. A downside of TJR is that obesity and age are also
risk factors associated to PJI [39]; ALBCs are routinely used to prevent and treat such occur-
rences. Unfortunately, PJI can establish well after the bone cement has ceased releasing antibi-
otic; hence, novel technologies capable of prolonging the release of antibiotics from bone
cements are urgently needed [40]. Silica nanoparticles loaded with gentamicin through LbL
have shown ability to sustain antibiotic release for ~4 wk [31]. The purpose of the present
study was to determine whether such nanocarriers could be mixed in commercial bone
cements, resulting in sustained antibiotic release, without negative impact on other properties.
For this purpose, we used bone cements brands produced by two different manufacturers
(characterised by different composition/concentration of radio-opacifier, polymer used and
amount of antibiotic).
Settling time is a critical parameter for bone cement use during application and after patient
recovery, because it determines the time available to the surgeon to apply the bone cement and
the time needed to develop the final mechanical properties of the cement. NP-GEN-containing
bone cements (Cemex-NP-GEN and Palacos R-NP-GEN) were not inferior in terms of settling
time (Fig 1) than the equivalent commercial formulation (Cemex Genta and Palacor R+G,
respectively). The setting time depends on the polymerisation of methyl methacrylate and
PMMA and, because of the significant amount of granular material present in the bone cement
Table 3. Gentamicin MIC of clinical isolates tested.
Strain MIC (μg/mL)
S. pneumonia 59413 8
P. aeruginosa 59224 8
S. epidermidis 59174 4
E. coli 59284 8
https://doi.org/10.1371/journal.pone.0207753.t003
Si-GS nanocarriers for antimicrobial bone cement
PLOS ONE | https://doi.org/10.1371/journal.pone.0207753 December 13, 2018 11 / 22
Fig 3. Summary of the antimicrobial test results (n=6±SD) (a) and expected versus observed antimicrobial activity (b).
https://doi.org/10.1371/journal.pone.0207753.g003
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Fig 4. Summary of mitochondrial activity of osteoblasts exposed to bone cements assessed through MTT (n=6±SD).
https://doi.org/10.1371/journal.pone.0207753.g004
Fig 5. Summary of cytocompatibility test results, assessed through LDH assay: (n=6±SD).
https://doi.org/10.1371/journal.pone.0207753.g005
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as radio opacifiers, the addition of the required amount of NP-GEN did not influence the
kinetic of polymerisation. The present G’ and G’’ profiles were comparable to those presented
by others for PMMA bone cements [34, 41].
Fig 6. Summary of the cytocompatibility test results, assessed through Alizarin Red assay (n=6±SD).
https://doi.org/10.1371/journal.pone.0207753.g006
Fig 7. Summary of the images of the live cells (green color), dead cells (red color), and cell nuclei (blue color).
(Top panels: 100 μm bar, bottom panels: 20 μm bar).
https://doi.org/10.1371/journal.pone.0207753.g007
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The concentration of NP-GEN used in the bone cement was calculated in order to have
equivalent amount of gentamicin to the commercial cements. Cemex-NP-GEN exhibited pro-
longed release, the reason for this behaviour being that the antibiotic needs first to be released
from the coating on the silica NP before it can migrate through the bone cement matrix. Gen-
tamicin exhibits high diffusivity through PMMA bone cements, resulting in burst release from
commercial formulations, but the antibiotic is gradually made available and, thus, the release
occurs over a longer period of time. The use of NP-GEN did not extend the release of gentami-
cin in Palacos as these cements are prepared with smaller amount of gentamicin (Table 1) and
the antibiotic concentration fell below detection limits before the effect of the nanocarriers
could be observed. Moreover, the enhanced total amount of gentamicin released from the
bone cement (26% of GEN) by 2-3 folds compared to the commercial formulation noticed in
Cemex-NP-GEN could be the result of the homogenous distribution of NP-GEN in the bone
cement matrix, which may lead to the formation of nano-network channels to facilitate the dif-
fusion of GEN [42].
The prolonged antimicrobial activity against rapidly proliferating pathogens of Cemex-
NP-GEN compared to Cemex Genta (Fig 3) is the result of the antibiotic concentration
remaining above MIC for longer periods of time. As Palacos-NP-GEN and Palacos R+G exhib-
ited similar release profiles, the antimicrobial activity was not expected to be different. Antimi-
crobial activity against pathogens routinely associated to PJI [43, 44] was due to the presence
of GEN above MIC. Moreover, the different inhibitory activity determined on the variety of
pathogens employed depends on the bacteria susceptibility to antibiotic; that is, not species
specific, but, also, strain dependent. Moreover, we employed planktonic cells that are normally
more susceptible to antimicrobial compounds that their adhering (biofilms) counterparts [45].
Longer antimicrobial inhibition than expected (simply based on gentamicin concentrations)
were observed here (Fig 3B); which allowed us to hypothesize that unreacted monomer was
Fig 8. Summary of the images of the actin/dapi filaments (red color) and the cell nuclei (blue color). (Top panel:
100 μm bar, bottom panel: 20 μm bar).
https://doi.org/10.1371/journal.pone.0207753.g008
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also released from bone cement specimens. The presence of unreacted methyl methacrylate is
a well-known [46] phenomenon and such a compound is likely to synergistically contribute to
the antimicrobial activity exhibited by the release media. The release of methyl methacrylate is
also likely to decrease with time (similarly to antibiotics), thus, the effect would terminate and
the observed duration of antimicrobial activity on strains with low MIC should be closer to the
expected. The greater disparity between observed and expected antimicrobial duration for
Palacos than Cemex could be attributed to low GEN concentration measured in the release
media (and corresponding short expected antimicrobial duration). Remarkably, the antimi-
crobial duration in Cemex-NP-GEN was nearly as expected for strains with low MIC; these
would be inhibited for longer when methyl methacrylate release had already ended, leaving of
GEN as inhibitory compound in the release media.
Successful TJR requires osseointegration of the device through osteoblasts growth on the
bone cements. This material does not represent an optimal substrate for cells growth [47, 48],
this was also visible in the acting staining images (Figs 7 and 8) and in the LDH assay results
Fig 9. Summary of compressive strength bone cement bone cements before (grey column) and after aging in PBS, at 37 ºC,
for 3 mo (black columns) (n=5±SD).
https://doi.org/10.1371/journal.pone.0207753.g009
Table 4. Mechanical properties of the Cemex bone cements.
Bending strength (MPa) Bending modulus (MPa) Fracture toughness (MPa
p
m)
Cemex Genta 54.3 ± 2.0 2901 ± 62 2.4 ± 0.5
Cemex-NP-GEN 51.2 ± 4.1 2964 ± 101 2.2 ± 0.3
https://doi.org/10.1371/journal.pone.0207753.t004
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(Fig 5); but bone cements cytocompatibility is sufficient as they are routinely employed. Our
experiments were, therefore, interested in demonstrating the non-inferiority of the bone
cement with mixed NP-GEN compared to the corresponding commercial formulation using
biochemical assays (Figs 4, 5 and 6) and imaging (Figs 7 and 8). No differences were caused
by NPs addition in any of the tests as silica NPs are known to be highly biocompatible and also
the LbL coating is made with biocompatible polyelectrolytes.
Compressive strength (Fig 9), bending strength, bending modulus, and fracture toughness
(Table 4) were not affected by the addition of NP-GEN as the amount of nanocarriers mixed
is minimal compared to the already present non-polymeric constituents. Palacos has a higher
compressive strength than Cemex because of the different composition that also justifies the
different behaviour after aging (Cemex decreasing compressive strength after 3 mo while Pala-
cos retaining the compressive strength exhibited after preparation). Bending strength, bending
modulus, and fracture toughness were only tested for Cemex Genta and Cemex-NP-GEN
because the use of nanocarriers in Palacos cement was not able to prolong the release of GEN
(Fig 2).
Cemex-NP-GEN has a higher PBS intake than Cemex Genta (Fig 10) in the first hours of
contact with the liquid, after which the two bone cements absorbed similar amount of PBS. It
is possible that the NP-GEN induced the formation of more channels during polymerisation
which allowed more PBS to be adsorbed. Moreover, the higher PBS intake may also contribute
to the increased cumulative release of GEN.
Fig 10. Summary of the PBS uptake test results for different types of gentamicin containing bone cements after incubation in
PBS buffer, pH 7.4 (n=3±SD).
https://doi.org/10.1371/journal.pone.0207753.g010
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Two nanostructure-based gentamicin-loaded carriers have been studied to improve the
release profile of gentamicin from ALBCs [42, 49]. Shen et al. (2016) [42] used mesoporous sil-
ica nanoparticles (MSN) to improve gentamicin release from PMMA bone cement that contin-
ued for up to 80 days, where 60% of gentamicin was released. However, the concentration of
released gentamicin from MSN or the loading efficiency of MSN were not stated in the report.
In the present study, the loading efficiency of GEN in the NP-GEN was ~30% (w/w), which is
lower than that in MSN [42]. This is because MSNs have larger size (100–300 nm) with pores
in the range 5–30 nm allowing higher gentamicin loading inside the pores compared to
NP-GEN. Ayre et al. [49] loaded gentamicin into liposomes and antibiotic release from loaded
cement continued for up to 30 d, with 22% of the loaded antibiotic released. These results are
similar results to the present one. However, the addition of liposomes to bone cement did sig-
nificantly impact the compressive strength of the cement, whereas, in the present study, addi-
tion of NP-GEN did not do so.
For the determination of setting time, dynamic rheology was chosen over standard method
(ISO 5833 and ASTM F451) in order to provide a more objective result (as it does not require
operator decision) and more reproducible as ISO5833 results depends on, for example, the
brand of glove used [50]. Different protocols are used to evaluate the antimicrobial properties
of bone cements in literature beside counting surviving bacteria through plating. For example,
a high throughput technique based on the duration of apparent lag phase has been developed
by Bechert et al. (2000)[51] while agar diffusion test to evaluate the antimicrobial properties of
liposomal cement formulation [49]. Hence, there is not a standardised approach to estimating
antimicrobial activity. The protocol that we used has the advantage of allowing screening
numerous strains using the same specimens, which is not possible with diffusion test or any
other of the methodologies mentioned. A wide range of cytotoxicity assays (MTT, LDH, Aliza-
rin red and microscopy image) was employed in this study to provide a more comprehensive
validation of the drug delivery system as each test assesses a specific variable (such as MTT
mitochondrial activity, LDH cell integrity, Alizarin red calcium production and microscopy
cell morphology). Despite the need for long term in vivo trials to fully address cytocompatibil-
ity, in vitro data can provide indicative responses and, thus, the greater the number of tests the
greater the number of variables evaluated.
The present study has a number of limitations. First, the study was conducted using one set
of processing/fabrication conditions. It is likely that different outcomes would be obtained if
different polyelectrolytes were used during LbL (for example, PBAEs synthesised with other
acrylates and amine exhibiting varying zeta potential, length and kinetics of hydrolysis); Sec-
ond, the ability of the released GEN to inhibit formation of biofilms (a phenomenon that has
been widely reported to be implicated in PJI) [52, 53] was not investigated.
Conclusion
Lbl-coated silica nanoparticles in which gentamicin sulphate was incorporated have been suc-
cessfully mixed with the powder of a PMMA bone cement (NP-GEN cement). Compared to a
commercial counterpart cement, NP-GEN cement has comparable setting time (~4.5 min),
displayed GEN release that was more gradual and prolonged (burst phase duration of ~7 d ver-
sus ~1 d and exhaustion after ~22 d versus ~4 d), demonstrated significantly higher efficacy of
the eluted gentamicin against an assortment of bacterial strains, including those from clinical
isolates from infected TJRs (for example, Cemex-NP-GEN and Cemex Genta inhibited growth
of each of the bacterial strains from PJI isolates for ~19 ± 4 d and ~14 ± 8 d, respectively),
showed cytocompatibility (towards Saos-2 human osteosarcoma osteoblast-like cells), and
have comparable compressive strength (75 ± 4 MPa and 78 ± 2 before and after aging in PBS,
Si-GS nanocarriers for antimicrobial bone cement
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at 37 oC, for 3 mo), 4-point bend strength and modulus (52 ± 2 MPa and 2935 ± 15 MPa,
respectively), fracture toughness (2.3 ± 0.2 MPa
p
m), and PBS intake (a steady-state value of
~11 wt./wt.%). Thus, NP-GEN bone cement may have a role in preventing or treating PJI.
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